BiotechTube

teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis, Post-Menopausal

Conditions

Osteoporosis, Post-Menopausal

Trial Timeline

Jun 1, 2003 → Aug 1, 2004

NCT ID
NCT00543023

About teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous

teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneous is a phase 3 stage product being developed by Eli Lilly for Osteoporosis, Post-Menopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00543023. Target conditions include Osteoporosis, Post-Menopausal.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00542984Phase 3Completed
NCT00543023Phase 3Completed

Competing Products

20 competing products in Osteoporosis, Post-Menopausal

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
77
TeriparatideEli LillyPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
raloxifene + placeboEli LillyApproved
85
Teriparatide + Salmon CalcitoninEli LillyPhase 3
77
ForteoEli LillyPre-clinical
23
arzoxifene + PlaceboEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
77
YM529 / ONO-5920Astellas PharmaPhase 2/3
65
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85